Answers are grounded in this paper and cite their sources.
Real-world data suggest clinical remission is a feasible treatment goal of monoclonal antibody therapy. Evidence of ongoing response post-12 months may be used to inform treatment decisions. Further work is needed to standardise criteria for remission. https://bit.ly/4cA6TkG.
No takes yet. Share an insight, caveat, or question.
Fyles et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: